Kerstin Klein

Dr. Kerstin Klein

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Immunity
Verified
Journal Article
Closed access
JFJasna Friščić
Jasna Friščić
Martin BöttcherMartin Böttcher
Martin Böttcher
CRChristiane Reinwald
Christiane Reinwald
HBHeiko Bruns
Heiko Bruns
BWBenjamin Wirth
Benjamin Wirth
MHMarkus H Hoffmann
Markus H Hoffmann

23 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMojca Frank-Bertoncelj
Mojca Frank-Bertoncelj
MTMichelle Trenkmann
Michelle Trenkmann
KKKerstin Klein
Kerstin Klein
EKEmmanuel Karouzakis
Emmanuel Karouzakis
HRHubert Rehrauer
Hubert Rehrauer
COCaroline Ospelt
Caroline Ospelt
A number of human diseases, such as arthritis and atherosclerosis, include characteristic pathology in specific anatomical locations. Here we show transcriptomic differences in synovial fibroblasts from different joint locations and that HOX gene signatures reflect the joint-specific origins of mouse and human synovial fibroblasts and synovial tissues. Alongside DNA methylation and histone modifications, bromodomain and extra-terminal reader proteins regulate joint-specific HOX gene expression. Anatomical transcriptional diversity translates into joint-specific synovial fibroblast phenotypes with distinct adhesive, proliferative, chemotactic and matrix-degrading characteristics and differential responsiveness to TNF, creating a unique microenvironment in each joint. These findings indicate that local stroma might control positional disease patterns not only in arthritis but in any disease with a prominent stromal component.

1 February 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
KKKerstin Klein
Kerstin Klein
PKPawel A Kabala
Pawel A Kabala
AGAleksander Grabiec
Aleksander Grabiec
RGRenate E Gay
Renate E Gay
CKChristoph Kolling
Christoph Kolling
KRKris A Reedquist
Kris A Reedquist
Objective To investigate the effects of BET bromodomain protein inhibition on inflammatory activation and functional properties of rheumatoid arthritis synovial fibroblasts (RASF). Methods The expression of the BET bromodomain proteins BRD2, BRD3 and BRD4 was analysed in synovial tissue by immunohistochemistry. RASF were stimulated with tumour necrosis factor (TNF)-α, interleukin (IL)-1β and toll-like receptor (TLR) ligands (Pam3, pIC and lipopolysaccharide (LPS)) in the presence or absence of the BET inhibitor I-BET151, or siRNA targeting BRD2, BRD3 and BRD4. RASF expression of inflammatory mediators, including MMP1, MMP3, IL-6 and IL-8, was measured by q-PCR, q-PCR array and ELISA. Cellular viability, apoptosis, proliferation and chemoattractive properties of RASF were investigated using MTT, cell apoptosis ELISA, BrdU-based proliferation and transwell migration assays. Results BRD2, BRD3 and BRD4 proteins were detected in rheumatoid arthritis (RA) synovial tissue, expressed in both RASF and macrophages. I-BET151 suppressed cytokine and TLR ligand-induced secretion of MMP1, MMP3, IL-6 and IL-8, and mRNA expression of more than 70% of genes induced by TNF-α and IL-1β. Combined silencing of BRD2, BRD3 and BRD4 significantly reduced cytokine and TLR ligand-induced expression of a subset of gene products targeted by I-BET151, including MMP1, CXCL10 and CXCL11. I-BET151 treatment of RASF reduced RASF proliferation, and the chemotactic potential for peripheral blood leucocytes of RASF conditioned medium. Conclusions Inhibition of BET family proteins suppresses the inflammatory, matrix-degrading, proliferative and chemoattractive properties of RASF and suggests a therapeutic potential in the targeting of epigenetic reader proteins in RA.

10 September 2013 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MKMasaru Kato
Masaru Kato
COCaroline Ospelt
Caroline Ospelt
RGRenate E. Gay
Renate E. Gay
SGSteffen Gay
Steffen Gay
KKKerstin Klein
Kerstin Klein
Objective: To investigate the role of autophagy in the regulation of cell death in rheumatoid arthritis synovial fibroblasts (RASFs).Methods: RASFs and osteoarthritis synovial fibroblasts (OASFs) were treated with thapsigargin (TG), an inducer of endoplasmic reticulum (ER) stress, and MG132, a proteasome inhibitor. Then, 3‐methyladenine was used as an autophagy inhibitor and bafilomycin A1 as a lysosome inhibitor. Polyubiquitinated proteins, p62, and autophagy induction were evaluated by immunoblotting, immunofluorescence microscopy, and immunohistochemistry, respectively. OASFs were transfected with small interfering RNA targeting autophagy‐linked FYVE protein (ALFY). Cell death was evaluated by flow cytometry and a caspase 3 activity assay.Results: In RASFs, the induction of autophagy by TG and MG132 was increased compared to that in OASFs. Whereas autophagy promoted a caspase 3–independent induction of cell death under ER stress, autophagy had a protective role in apoptosis induced by proteasome inhibition. Treatment of RASFs with 3‐methyladenine blocked TG‐induced cell death. ER stress induced a strong accumulation of p62‐positive polyubiquitinated protein aggregates, accompanied by the formation of large vacuoles in RASFs but not OASFs. Furthermore, TG‐induced p62 protein expression was increased, whereas TG‐induced ALFY expression was reduced, in RASFs compared to OASFs. ALFY knockdown promoted the accumulation of p62, the formation of polyubiquitinated protein aggregates, and cell death.Conclusion: Our data provide the first evidence of a dual role of autophagy in the regulation of death pathways in RASFs. A reduced expression of ALFY and the formation of p62‐positive polyubiquitinated protein aggregates promote cell death in RASFs under severe ER stress.

1 January 2015 in Current Opinion in Rheumatology
Verified
Journal Article
Closed access
KKKerstin Klein
Kerstin Klein
SGSteffen Gay
Steffen Gay
To give an overview of recently published articles addressing the role of epigenetic modifications in rheumatoid arthritis (RA). Here we focused on DNA methylation and posttranslational histone modifications. Recent studies attempted to link epigenetic modifications with genetic or environmental risk factors for RA. There is evidence that histone deacetylases confer effects of environmental triggers such as smoking, diet or therapy on expression levels of target genes. Additionally, disturbed methylation patterns and cell-type specific histone methylation marks were identified as potential mediators of genetic risk in RA. Altered methylome signatures were found in several cell types in RA, first of all RA synovial fibroblasts, and contribute to the intrinsic fibroblast activation. The reversal of DNA hypomethylation by inhibiting the polyamine recycling pathway was suggested as new epigenetic therapy in RA. Moreover, targeting epigenetic reader proteins, such as bromodomain proteins, emerged as a new field in drug development and the first studies underscored the potential of these drugs not only in malignant and inflammatory conditions but also in autoimmune diseases. Epigenetic factors represent a promising area to link genetics, regulation of gene expression and environmental risk factors.

21 March 2017 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
COCaroline Ospelt
Caroline Ospelt
SGSteffen Gay
Steffen Gay
KKKerstin Klein
Kerstin Klein